Related Experiment Video
Updated: Aug 1, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
[Ambulant treatment of hypertension with cardiotensin (author's transl)]
Insights
This study shows a fixed combination of a beta-blocker and diuretics effectively treats essential hypertension. Patients experienced significant blood pressure reduction and improved exercise capacity with good tolerance and high compliance.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Essential hypertension (WHO grades I and II) affects a significant portion of the adult population.
- Current treatment strategies often involve combination therapy to achieve optimal blood pressure control.
Purpose of the Study:
- To evaluate the efficacy and safety of a fixed combination preparation of a beta-blocker and diuretics in treating essential hypertension.
- To assess the impact of the combination therapy on blood pressure, exercise capacity, and patient compliance.
Main Methods:
- A randomized, placebo-controlled trial involving 25 outpatients with essential hypertension.
- Treatment duration was 8 weeks, with blood pressure monitored regularly.
- Ergometric load testing was performed to assess cardiovascular response to exercise.
Main Results:
- The fixed combination significantly reduced elevated blood pressure to normal levels within 8 weeks.
- Significant improvements were observed in blood pressure increase during exercise, increased load capacity, and decreased pressure-rate product.
- The treatment demonstrated good tolerance, with mild side effects in 10 patients and no clinically significant changes in laboratory values.
Conclusions:
- Fixed combination therapy with a beta-blocker and diuretics is an effective and well-tolerated treatment for essential hypertension.
- This combination improves hemodynamic responses to exercise and enhances patient compliance.
Abstract:
A fixed combination preparation consisting of a betablocker and diuretics was tested in 25 outpatients suffering from essential hypertension grades I and II (WHO). The raised blood pressures of the placebo phase fell highly significantly to normal values in th course of the 8 weeks' treatment. The ergometric load testing under standardized conditions showed a significant reduction of blood pressure increase, a significant rise in load capacity, and a decrease in the pressure rate product. Apart from the increase in serum acid in one case, no clinically relevant changes in the laboratory values were observed. Tolerance was good. The side effects mentioned by 10 patients were mild and did not influence the course of treatment. Patient compliance, measured twice in th course of the trial by means of urine fluorescence, was very high (95%).
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiomyopathy V: Interprofessional Care
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension V: Nursing Management

